Diagnostic Technology

About TpP
Point of Care
Clinical Results
ABS has developed an accurate and flexible diagnostic assay called the Thrombus Precursor Protein (TpPTM) test. TpP measures blood levels of soluble fibrin, which is the immediate precursor to a key component of blood clots. This FDA approved test aids in the risk assessment of thrombosis (blood clot formation) in conditions such as deep vein thrombosis, pulmonary embolism and myocardial infarction and monitor anticoagulant therapy. TpP offers physicians the right information at the right time, and allows them to make the vest possible treatment decision. It is estimated that the worldwide market for the TpP test is 350 million tests annually.

— — — — — — —

• More than 5 million people present to emergency rooms annually with chest pain, but only 15% are actually experiencing a myocardial infarction.

• Some 600,000 patients develop pulmonary embolism (PE) and 60,000 die of PE annually. This exceeds the number of American women who die each year of breast cancer.

• PE is now the most frequent cause of death associated with childbirth.

• Deep-vein thrombosis (DVT) occurs in 2 million Americans each year, and patients with DVT are prone to recurrent episodes, increasing mortality risk, cost, and hospitalization

• High-risk procedures for PE/DVT include:
ΡΡ – Cardiopulmonary Bypass
ΡΡ – Coronary Artery Bypass
ΡΡ – Percutaneous Transluminal Coronary Angioplasty

• Early detection of life threatening conditions such as acute MI provides physicians with an important window of opportunity during which life-saving drugs can be administered.

• Even more clinical trials are currently underway — trials that will further highlight the advantages of TpP over competing tests, while continuing to raise the test's profile among hematologists, cardiologists, emergency room physicians and laboratory technologists.


American Biogenetic Sciences, Inc. ©2000